HIV, Buprenorphine, and the Criminal Justice System

• Status: Completed
• Trial end date: 2016-11-30
• Target enrollment: 0
• Participant gender: All

Summary

The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a longitudinal, non-randomized, observational study design. The population under study consists of individuals living with HIV who are dependent on opioids.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborators: George Mason University; Howard University; National Institute on Drug Abuse (NIDA)
• Treatments: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Naloxone

Criteria

Inclusion Criteria:

• HIV+

• Age ≥18 yrs

• Meets DSM-IV criteria for opioid dependence

• Has medical entitlements in DC

• Able to provide informed consent

• Able to communicate in English or Spanish

Exclusion Criteria:

• Being prescribed an opiate medication for a chronic pain condition or expressing the need to be placed on chronic pain medical conditions for a documented pain condition

• Currently receiving methadone dosing of over 30 mg per day and uninterested in changing to buprenorphine

• AST and ALT >5x the upper limit of normal (AST≥175, ALT≥195)

• Pregnant or unwilling to use contraception (including OCPs, patch, Depo-Provera, condoms, etc.)

• Breastfeeding or unwilling to stop breastfeeding

• Subject is part of another pharmacological research study

• Liver dysfunction (acute hepatitis, liver failure or hepatic dysfunction)

• Suicidal ideation

• Hypersensitivity to buprenorphine